Clinical trial
A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line…
NCT00257608 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00257608 |
|---|---|
| Title | A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS) |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab Therapy With or Without Erlotinib After Completion of Chemotherapy With Bevacizumab for the First-Line Treatment of Locally Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | bevacizumab, placebo, erlotinib HCl |
| Enrollment | 1,145 |
| Start date | Jan 1, 2006 |
| Primary completion | Nov 1, 2014 |
| Completion | Nov 1, 2014 |
| First posted | Nov 23, 2005 |
| Last update posted | Apr 18, 2016 |
| Countries | Argentina, Australia, Belgium, Brazil, Bulgaria, Hong Kong, Israel, Italy, Mexico, Philippines, Romania, Singapore and 5 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: